Medical Device Product Recall Management

Recall Execution

21 CFR Part 806: When Notification Is Required and What It Must Contain

Under 21 CFR Part 806, manufacturers must report to FDA within 10 working days after initiating a correction or removal of a device from the market if the action is undertaken to reduce a risk to health posed by the device, or to remedy a violation of the FD&C Act caused by the device. This is a mandatory notification requirement — failing to report a correction or removal that meets this threshold is itself a violation. The 10-day clock starts when the decision is made to take the corrective action, not when the action is completed.

The content requirements of a 806 notification are specific: device identification (name, catalog number, lot/serial numbers affected), reason for the action, number of devices distributed and the distribution period, method of correction or removal, recall classification expectation, contact information, and copies of all communications with distributors and customers. FDA will assign the recall a classification (Class I, II, or III) based on health hazard assessment, and the classification determines the visibility and urgency requirements of the recall strategy. Class I recalls — where there is a reasonable probability of serious adverse health consequences — receive the most urgent FDA oversight.

Recall Strategy: Depth, Communication, and Consignee Management

The recall strategy defines the depth of the recall (consumer level, retail, wholesale, or manufacturer only), the communication vehicle and content, and the timeline for consignee notification and response. For Class I and II recalls, FDA reviews and may direct modifications to the recall strategy. Recall communications must be written clearly and without minimizing the seriousness of the action — communications that appear to downplay health risk or that make it difficult for consignees to identify affected devices are a compliance problem that FDA will require correction.

Consignee management — tracking the disposition of all distributed devices — is the operational core of a recall. Distribution records must be sufficient to identify all consignees within the affected lot or serial number range. Companies with inadequate distribution tracking find themselves attempting a recall with an incomplete consignee list, which both extends the recall timeline and creates FDA concern about the adequacy of the corrective action. We assess distribution record adequacy at recall initiation and develop consignee tracking strategies appropriate to the scope of the recall.

Effectiveness Checks and Recall Closure

FDA requires effectiveness checks to verify that consignees have received and responded to the recall communication. The effectiveness check methodology — typically a percentage-based audit of consignees at different distribution levels — must be documented and reported to FDA. Recalls remain open until FDA is satisfied that the effectiveness check demonstrates adequate consignee response and that all recovered or remediated devices have been accounted for. A recall that is executed quickly and closed efficiently causes far less disruption than one that drags for months due to inadequate tracking or incomplete effectiveness documentation.

What We Deliver

• Recall trigger assessment: 21 CFR 806 reportability determination
• FDA 806 notification package: all required content elements
• Recall strategy development: depth, communication, consignee management
• Recall communication writing: clear, compliant, FDA-reviewable letters
• Consignee tracking system and distribution record assessment
• Effectiveness check design and execution documentation
• FDA recall status reporting and correspondence management
• Recall CAPA development: root cause analysis and corrective action for recurrence prevention
• Recall closure documentation and FDA closure request

Get Recall Management Support